Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2020 | 2019 | 2018 | 2017 | 2016
Number of items: 13.

2020

Armand, Philippe, Murawski, Niels, Molin, Daniel, Zain, Jasmine, Eichhorst, Barbara, Gulbas, Zafer, Hawkes, Eliza A., Pagel, John M., Phillips, Tycel ORCID: 0000-0003-2143-9672, Ribrag, Vincent, Svoboda, Jakub, Stathis, Anastasios, Chatterjee, Arkendu, Orlowski, Robert, Marinello, Patricia and Christian, Beth (2020). Pembrolizumab in relapsed or refractory Richter syndrome. Br. J. Haematol., 190 (2). S. E117 - 4. HOBOKEN: WILEY. ISSN 1365-2141

Zinzani, Pier Luigi, Chen, Robert, Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John ORCID: 0000-0001-7898-2786, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Lin, Jianxin, Nahar, Akash, Balakumaran, Arun and Moskowitz, Craig H. (2020). Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leuk. Lymphoma, 61 (4). S. 950 - 955. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

2019

Chen, Robert, Zinzani, Pier Luigi, Lee, Hun Ju, Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Lin, Jianxin, Kim, Eunhee, Nahar, Akash, Balakumaran, Arun and Moskowitz, Craig H. (2019). Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood, 134 (14). S. 1144 - 1154. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

2018

Armand, Philippe, Engert, Andreas, Younes, Anas, Fanale, Michelle, Santoro, Armando ORCID: 0000-0003-1709-9492, Zinzani, Pier Luigi, Timmerman, John M., Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trneny, Marek, Shipp, Margaret A., Kato, Kazunobu, Sumbul, Anne, Farsaci, Benedetto ORCID: 0000-0001-8275-2561 and Ansell, Stephen M. (2018). Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J. Clin. Oncol., 36 (14). S. 1428 - 1450. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Armand, Philippe, Engert, Andreas, Younes, Anas, Lee, Hun Ju, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John M., Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Savage, Kerry J., Kuruvilla, John, Trneny, Marek, Shipp, Margaret A., Sacchi, Mariana, Ansell, Anne Sumbuland Stephen M. and Ansell, Stephen M. (2018). Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cohen, Jonathon B., Kuruvilla, John, Engert, Andreas, Ansell, Stephen M., Younes, Anas, Lee, Hun Ju, Trneny, Marek, Savage, Kerry J., Ramchandren, Radhakrishnan, Collins, Graham P., Zinzani, Pier Luigi, De Boer, Jan Paul, Shipp, Margaret A., Santoro, Armando, Timmerman, John M., Sacchi, Mariana, Sy, Oumar and Armand, Philippe (2018). Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Roemer, Margaretha G. M., Redd, Robert A., Cader, Fathima Zumla, Pak, Christine J., Abdelrahman, Sara, Ouyang, Jing, Sasse, Stephanie, Younes, Anas, Fanale, Michelle, Santoro, Armando ORCID: 0000-0003-1709-9492, Zinzani, Pier Luigi, Timmerman, John, Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trneny, Marek, Ansell, Stephen, Kato, Kazunobu, Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Sumbul, Anne, Armand, Philippe, Neuberg, Donna S., Pinkus, Geraldine S., Ligon, Azra H., Rodig, Scott J. and Shipp, Margaret A. (2018). Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J. Clin. Oncol., 36 (10). S. 942 - 954. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

2017

Chen, Robert, Zinzani, Pier Luigi, Fanale, Michelle A., Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Zhang, Yinghua, Ricart, Alejandro D., Balakumaran, Arun and Moskowitz, Craig H. (2017). Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J. Clin. Oncol., 35 (19). S. 2125 - 2135. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

2016

Moskowitz, Craig H., Zinzani, Pier Luigi, Fanale, Michelle A., Armand, Philippe, Johnson, Nathalie A., Radford, John A., Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Gustafson, Eric, Zhang, Yinghua, Ricart, Alejandro Daniel, Balakumaran, Arun and Chen, Robert W. (2016). Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Roemer, Margaretha G. M., Ligon, Azra H., Engert, Andreas, Younes, Anas, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John M., Ansell, Stephen, Armand, Philippe, Fanale, Michelle A., Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B., Collins, Graham P., Savage, Kerry J., Trneny, Marek, Neuberg, Donna S., Redd, Robert A., Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Kato, Kazunobu, Sumbul, Anne, Rodig, Scott J. and Shipp, Margaret A. (2016). Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Timmerman, John M., Engert, Andreas, Younes, Anas, Santoro, Armando, Armand, Philippe, Fanale, Michelle A., Collins, Graham P., Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B., Savage, Kerry J., Trneny, Marek, De Boer, Jan Paul, Shipp, Margaret A., Rodig, Scott J., Kato, Kazunobu, Sumbul, Anne and Ansell, Stephen (2016). Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Younes, Anas, Santoro, Armando ORCID: 0000-0003-1709-9492, Shipp, Margaret, Zinzani, Pier Luigi, Timmerman, John M., Ansell, Stephen, Armand, Philippe, Fanale, Michelle, Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B., Collins, Graham ORCID: 0000-0002-8803-4234, Savage, Kerry J., Trneny, Marek ORCID: 0000-0002-6952-6073, Kato, Kazunobu, Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Parker, Susan M., Rodig, Scott, Roemer, Margaretha G. M., Ligon, Azra H. and Engert, Andreas (2016). Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol., 17 (9). S. 1283 - 1295. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Younes, Anas, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John, Ansell, Stephen Maxted, Armand, Philippe, Fanale, Michelle A., Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon Brett, Collins, Graham P., Savage, Kerry J., Trneny, Marek, Kato, Kazunobu, Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Parker, Susan M., Rodig, Scott J., Shipp, Margaret Ann and Engert, Andreas (2016). Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) A phase 2 study. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

This list was generated on Fri Apr 19 12:45:06 2024 CEST.